| (Values in U.S. Thousands) | Mar, 2026 | Sep, 2025 | Jun, 2025 | Mar, 2025 | Sep, 2024 |
| Sales | 13,405,000 | 11,438,000 | 9,660,000 | 10,739,000 | 13,738,000 |
| Sales Growth | +17.20% | +18.41% | -10.05% | -21.83% | +17.13% |
| Net Income | 2,763,000 | -3,757,000 | -963,000 | -199,000 | 1,299,000 |
| Net Income Growth | +173.54% | -290.14% | -383.92% | -115.32% | +487.76% |
Bayer Ag (BAYN.D.DX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [DXE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [DXE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Bayer is a German healthcare and agriculture conglomerate. Healthcare provides close to half of the company's sales and includes pharmaceutical drugs (about 38% of total sales in 2025) as well as vitamins and other consumer healthcare products (13% of total). The firm's crop science business (47% of total) sells seeds, pesticides, herbicides, and fungicides, which was expanded through its 2018 acquisition of Monsanto.
Fiscal Year End Date: 12/31